# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-263589
Filing Date
2025-11-04
Accepted
2025-11-04 07:30:47
Documents
52
Period of Report
2025-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | kura-20250930.htm iXBRL | 10-Q | 2467636
2 | EX-10.2 | kura-ex10_2.htm | EX-10.2 | 57036
3 | EX-31.1 | kura-ex31_1.htm | EX-31.1 | 12239
4 | EX-32.1 | kura-ex32_1.htm | EX-32.1 | 10349
| Complete submission text file | 0001193125-25-263589.txt |  | 8087701

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | kura-20250930.xsd | EX-101.SCH | 940858
55 | EXTRACTED XBRL INSTANCE DOCUMENT | kura-20250930_htm.xml | XML | 1341312

Mailing Address 4930 DIRECTORS PLACE, SUITE 500 SAN DIEGO CA 92121
Business Address 4930 DIRECTORS PLACE, SUITE 500 SAN DIEGO CA 92121 (858) 500-8800
Kura Oncology, Inc. (Filer) CIK: 0001422143 (see all company filings)

EIN.: 611547851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37620 | Film No.: 251446458
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)